GD2-SADA

Y-mAbs Therapeutics presented Phase 1 Trial 1001 data for its GD2-SADA PRIT therapy at the Neuroblastoma Research Meeting, targeting recurrent/refractory GD2-positive solid tumors (neuroblastoma, lung cancer, sarcoma, melanoma). The two-step approach combines non-radioactive GD2-SADA proteins with Lutetium-177 to selectively irradiate tumors. Following Part A dose optimization, preliminary safety/efficacy results will be disclosed May 28th. If proven effective, this precision radiotherapy platform could address high-unmet needs across oncology markets, positioning YMAB for potential partnerships in the $6.8B radiopharma sector.